

 Bristol Myers Squibb™
U.S. Pharmaceuticals
3401 Princeton Pike, Lawrenceville, NJ 08648

March 27th, 2021

BY ELECTRONIC DELIVERY

Vermont Attorney General's Office
109 State Street
Montpelier, VT 05609
AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Bristol-Myers Squibb is providing notice of the introduction of a new prescription drug with a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program:

- ABECMA® (idecabtagene vicleucel) is supplied in one or more infusion bag(s) containing a frozen suspension of genetically modified autologous T cells in 5% DMSO concentration. Each (50/250/500 MI) infusion bag of ABECMA® is individually packed in a metal cassette.

NDC 59572-0515-01

NDC 59572-0515-02

NDC 59572-0515-03

This notice is provided within three calendar days following the release of the drug in the commercial market, as required by 18 V.S.A. § 4637(b). Since 18 V.S.A. § 4637 does not define "release of the drug in the commercial market," we have based our three-day notice on the date that the products became available for purchase by patients.

In the event Vermont S. 92 and the laws it implements, including 18 V.S.A. § 4637, are found invalid, Bristol-Myers Squibb reserves all of its legal rights. In issuing this notice in an attempt to comply with 18 V.S.A. § 4637, Bristol-Myers Squibb does not waive any legal claims or legal rights related to constitutional or other defects arising under Vermont S. 92.

Sincerely,

Amina Khan
Associate Director, State Price Transparency